Go Deep
Gufic Biosciences Limited
Gufic Biosciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,104 | 58.9 | 6.51 | 0.61 | 432.00 |
| Oct 2026 | 21,134 | 57.1 | 6.31 | 0.61 | 418.40 |
| Oct 2026 | 20,525 | 55.5 | 6.13 | 0.61 | 406.30 |
Gufic Biosciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,608,180,000.0 | 2,518,197,000.0 | 2,314,099,000.0 | 2,370,545,000.0 |
| Net Profit | 223,128,000.0 | 218,961,000.0 | 124,236,000.0 | 168,240,000.0 |
| EPS | 2.2 | 2.2 | 1.2 | 1.7 |
Gufic Biosciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 8,126,693,000.0 | 7,455,532,000.0 | 7,696,562,000.0 | 6,797,546,000.0 | — |
| Net Profit | 642,147,000.0 | 696,496,000.0 | 861,356,000.0 | 797,048,000.0 | — |
| EPS | 6.4 | 6.9 | 8.7 | 8.2 | — |
Gufic Biosciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 13,423,740,000.0 | 11,693,637,000.0 | 10,925,414,000.0 | 8,611,595,000.0 | — |
| Total Liabilities | 6,773,874,000.0 | 5,682,869,000.0 | 5,599,809,000.0 | 5,133,513,000.0 | — |
| Total Equity | 6,649,485,000.0 | 6,010,768,000.0 | 5,325,605,000.0 | 3,478,082,000.0 | — |
Owes vs Owns
Gufic Biosciences Limited owed ₹0.50 for every ₹1 it owned in Mar 2026, down from ₹0.60 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.50× | 0.49× | 0.51× | 0.60× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Gufic Biosciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 4.6%Receivables 22.2%Inventory 24.2%Fixed assets (tangible) 38.7%Other assets 9.8%
How it's funded — Mar 2026
Short-term debt 20.9%Long-term debt 7.8%Payables 14.8%Other liabilities 6.9%Shareholders' equity 49.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 62.2 | 15.7 | 1.1 | 28.6 |
| Receivables | 297.4 | 314.6 | 329.9 | 205.5 |
| Inventory | 324.5 | 216.9 | 200.5 | 183.5 |
| Fixed assets (tangible) | 518.9 | 524.7 | 474.2 | 328.5 |
| Intangible assets | 6.2 | 6.3 | 5.6 | 0.7 |
| Long-term investments | 1.8 | 1.8 | 1.8 | 0.8 |
| Other assets | 131.5 | 89.3 | 79.4 | 113.7 |
| Liabilities & equity | ||||
| Short-term debt | 280.1 | 179.9 | 163.1 | 120.7 |
| Long-term debt | 105.0 | 130.5 | 154.0 | 190.7 |
| Payables | 199.0 | 158.7 | 166.3 | 130.3 |
| Other liabilities | 93.2 | 99.2 | 76.7 | 71.7 |
| Shareholders' equity | 665.0 | 601.1 | 532.6 | 347.8 |
| Net tangible assets | 658.8 | 594.7 | 526.9 | 347.1 |
Gufic Biosciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 451,394,000.0 | 1,225,679,000.0 | -74,571,000.0 | -265,872,000.0 | — |
| Investing Activities | -309,642,000.0 | -707,773,000.0 | -1,023,889,000.0 | -1,907,265,000.0 | — |
| Financing Activities | 322,873,000.0 | -372,041,000.0 | 823,810,000.0 | 2,343,076,000.0 | — |